G. Cazalas

Hôpital Pellegrin

Papers

2

Total Citations

33

H-Index

2

About

Dr. G. Cazalas is a leading clinical researcher in urologic oncology, with a focused expertise in the comparative effectiveness of minimally invasive treatments for renal cell carcinoma (RCC). Their major contributions center on rigorously evaluating the outcomes of percutaneous thermal ablation (TA) against robotic-assisted partial nephrectomy (RAPN), particularly for larger, more complex cT1b tumors. Dr. Cazalas spearheaded the landmark AblatT1b study (UroCCR 80), a multicenter matched-pair analysis that directly compared these two nephron-sparing approaches. This pivotal work, published in 2023 and accumulating over 30 citations, provides critical evidence on oncologic efficacy, renal function preservation, and complication rates, helping to define the optimal role of ablation in an era of advanced 3D image-guided robotic surgery. By systematically analyzing real-world outcomes from multiple centers, Dr. Cazalas has advanced the clinical decision-making framework for treating T1b RCC, offering surgeons and patients clearer guidance on balancing tumor control with quality of life. Their research is essential reading for urologists and interventional radiologists navigating the evolving landscape of kidney cancer management.

Research Focus

Key Achievements

2
H-Index
2
Papers
33
Total Citations
17
Avg Citations/Paper
🏆 Most Cited Paper
A multicenter comparative matched-pair analysis of percutaneous tumor ablation and robotic-assisted partial nephrectomy of T1b renal cell carcinoma (AblatT1b study—UroCCR 80)
25 citations · 2023
📈 Most Prolific Year: 2023 (2 Papers)
🤝 Key Collaborators: 22
🏛 Institutions: Hôpital Pellegrin

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago